Thrombolytic Agents in the Treatment of Artificial-Valve Thrombosis in 15 Cases

1986 ◽  
Vol 16 (3) ◽  
pp. 102-105
Author(s):  
S. Witchitz
Keyword(s):  
Artificial Valve ◽  
Thrombolytic Agents ◽  
Valve Thrombosis

scholarly journals 888 Fibrinolytic therapy for right-sided artificial valve thrombosis — our long-term follow-up experience

2003 ◽  
Vol 4 ◽  
pp. S113
Author(s):  
B OBRENOVICKIRCANSKI ◽  
D BOSKOVIC ◽  
B VUJISICTESIC ◽  
I ELEZOVIC ◽  
D BOSKOVIC ◽  
...  
Keyword(s):  
Fibrinolytic Therapy ◽  
Artificial Valve ◽  
Valve Thrombosis ◽  
Long Term Follow Up

Investigation of Genetic Polymorphisms in Infective Endocarditis and Artificial Valve Thrombosis

2017 ◽  
Vol 39 (2) ◽  
pp. 63-66
Author(s):  
Aydin Tuncay ◽  
Elif Funda Sener ◽  
Omer Naci Emirogullari
Keyword(s):  
Infective Endocarditis ◽  
Genetic Polymorphisms ◽  
Artificial Valve ◽  
Valve Thrombosis

Thrombolytic Agents

2000 ◽  
Vol 4 (1) ◽  
pp. 75-77 ◽  
Author(s):  
David Green
Keyword(s):  
Thrombolytic Agents

Strategies for the Improvement of Thrombolytic Agents

1991 ◽  
Vol 66 (01) ◽  
pp. 088-110 ◽  
Author(s):  
H R Lijnen ◽  
D Collen
Keyword(s):  
Thrombolytic Agents

Assay Methods and Standard Preparations for Plasmin, Plasminogen and Urokinase in Purified Systems, 1967-1968

1969 ◽  
Vol 21 (02) ◽  
pp. 259-272 ◽  
Author(s):  
A. J Johnson ◽  
D. L Kline ◽  
Norma Alkjaersig
Keyword(s):  
Heart Institute ◽  
Thrombolytic Agents ◽  
National Heart ◽  
Assay Methods

SummaryTo facilitate communication between investigators, the Committee on Thrombolytic Agents of the National Heart Institute suggests standardized reagents and assay methods for the measurement of standard preparations of plasmin, plasminogen, and urokinase with use of casein, fibrin and synthetic esters as substrates.

Acyl-Enzymes as Thrombolytic Agents in a Rabbit Model of Venous Thrombosis

1982 ◽  
Vol 47 (03) ◽  
pp. 269-274 ◽  
Author(s):  
R A G Smith ◽  
R J Dupe ◽  
P D English ◽  
J Green
Keyword(s):  
Venous Thrombosis ◽  
Active Site ◽  
Fibrinolytic Activity ◽  
Rabbit Model ◽  
Fibrinolytic Agent ◽  
Essential Nature ◽  
Thrombolytic Agents

SummaryA derivative of human lys-plasmin in which the active site has been reversibly acylated (BRL 26920; p-anisoyl human lys-plasmin) has been examined as a fibrinolytic agent in a previously described rabbit model of venous thrombosis and shown to be significantly more active and less fibrinogenolytic than free plasmin. A p-anisoylated derivative of a streptokinase (SK)-activated plasmin preparation was significantly less fibrinogenolytic in vivo than the non-acylated enzyme. Acylation increased the fibrinolytic activity of preparations of SK-plasmin activator complexes. BRL 26921, the active site anisoylated derivative of the primary 2-chain SK-plasminogen complex was the most potent fibrinolytic agent studied. SK-Val442-plasminogen complexes, free or acylated, were biologically inactive in this model and confirm the essential nature of fibrin binding processes for effective thrombolysis in vivo.

Comparative efficacy of various thrombolytic agents in treatment of pulmonary embolism

2019 ◽  
Vol 25 (3) ◽  
pp. 23
Author(s):  
N. G. Khorev ◽  
A. V. Beller ◽  
E. V. Borovikov ◽  
V. O. Konkova ◽  
Ya. N. Shoikhet
Keyword(s):  
Pulmonary Embolism ◽  
Comparative Efficacy ◽  
Thrombolytic Agents

Pregnancy-Related Cardiovascular Complications: Case Presentation and Review of Literature

2016 ◽  
Vol 19 (5) ◽  
pp. E248-E254 ◽  
Author(s):  
Hasan Baki Altinsoy ◽  
Ozkan Alatas ◽  
Salih Colak ◽  
Hakan Atalay ◽  
Omer Faruk Dogan
Keyword(s):  
Cardiac Surgery ◽  
Cesarean Section ◽  
Pregnant Women ◽  
Median Time ◽  
Artery Bypass ◽  
Prosthetic Heart Valve ◽  
Cardiovascular Complications ◽  
Time To Diagnosis ◽  
Valve Thrombosis ◽  
Placental Blood

Background: Cardiovascular complications that can cause severe catastrophic outcomes for both the mother and the fetus are rarely seen during pregnancy. Time to diagnosis is often delayed by a low degree of suspicion and atypical presentation. We report surgical strategies in three pregnant women with cardiovascular complications. Methods: A retrospective search from 2009 to 2016 identified three pregnant women who underwent urgent cardiac surgery. We used extracorporeal circulation (ECC) without cesarean section with careful follow-up of the fetuses during the perioperative and postoperative period. We used levosimendan as a potent inodilator in all patients to increase feto-placental blood flow and fetal heart rhythm.Results: Median time to diagnosis was 23.8 h (range 11.7-120 h) and median time from diagnosis to arrival in the operating theater was 9.8 h (range 7.4-19.8 h). One patient with prosthetic heart valve thrombosis underwent concomitant cesarean section prior to cardiac surgery. In a young pregnant woman who had spontaneous dissection of the left anterior descending artery, on-pump beating heart coronary artery bypass grafting was performed without cross clamping. Two and three months after surgery, cesarean sections were performed without any complication in two pregnant women.Conclusion: Because unusual cardiovascular complications are the main cause of maternal and/or fetus death during pregnancy, prompt and exact diagnosis is very important. Life-saving surgical strategy with the help of appropriate teams are necessary to optimize outcome for both mother and baby.

Sign in / Sign up

Export Citation Format

Share Document